论文部分内容阅读
目的比较中国和日本人胰腺浸润性导管癌中pBcl-2和pBax的表达情况,研究二者与胰腺癌患者预后之间的关系。方法采用免疫组织化学方法,检测59例中国和65例日本胰腺浸润性导管癌患者癌组织中pBcl-2和pBax的表达情况,并进行比较。结果在59例中国患者中,pBcl-2和pBax的阳性表达率分别为35.6%和49.2%;在65例日本患者中,二者的阳性表达率分别为23.1%和64.7%。在男性患者和组织学中分化的患者中,pBcl-2的表达中日间差异有显著性(χ2=4.447,P=0.035;χ2=4.114,P=0.043);在65岁以上人群中,pBax的表达中日间差异也有显著性(χ2=6.657,P=0.010)。中日pBcl-2(+)组患者的术后中位生存时间与pBcl-2(-)组相比差异有显著性(χ2=9.99,P=0.0016;χ2=7.63,P=0.0058);日本pBax(+)组患者的术后中位生存时间与pBax(-)组相比差异有显著性(χ2=9.37,P=0.0022);中日pBcl-2(+)组之间及pBax(+)组之间术后生存时间相比差异均有显著性(χ2=4.48,P=0.0342;χ2=5.23,P=0.023)。结论pBcl-2和pBax在中日胰腺癌患者中均有较高的表达。在中日两国患者中,pBcl-2表达均提示较好的预后。pBax表达在日本患者中可提示较好的预后,而在中国患者中却没有显著意义。
Objective To compare the expression of pBcl-2 and pBax in pancreatic invasive ductal carcinoma between Chinese and Japanese, and to study the relationship between them and the prognosis of patients with pancreatic cancer. Methods Immunohistochemical method was used to detect the expression of pBcl-2 and pBax in 59 cases of Chinese and 65 cases of pancreatic ductal carcinoma of the pancreas in Japan, and compared. Results The positive rates of pBcl-2 and pBax in 35 Chinese patients were 35.6% and 49.2%, respectively. Among 65 Japanese patients, the positive rates of pBcl-2 and pBax were 23.1% and 64.7% respectively. There was a significant difference between daytime and daytime in the expression of pBcl-2 in male patients and histological differentiation (χ2 = 4.447, P = 0.035; χ2 = 4.114, P = 0.043) There was also significant difference between daytime and daytime (χ2 = 6.657, P = 0.010). The median postoperative survival time in pBcl-2 (+) group was significantly different from that in pBcl-2 (χ2 = 9.99, P = 0.0016; χ2 = 7.63, P = 0.0058) The median postoperative survival time of pBax (+) group was significantly different from that of pBax (-) group (χ2 = 9.37, P = 0.0022) There was significant difference in the survival time between the two groups (χ2 = 4.48, P = 0.0342; χ2 = 5.23, P = 0.023). Conclusion Both pBcl-2 and pBax are highly expressed in Chinese and Japanese patients with pancreatic cancer. In both patients in China and Japan, pBcl-2 expression suggest a better prognosis. Expression of pBax in Japanese patients may suggest a better prognosis, but not significant in Chinese patients.